LONDON, February 22, 2016 /PRNewswire/ --
Dechra Pharmaceuticals PLC (LSE: Symbol: DPH Sector: Pharmaceuticals)
For more information or to download the full news release, please visit: http://www.dechra.com
“Strong first half performance reported by veterinary pharma specialists, Dechra”
“All our business units are performing well, we are in the process of launching several new products, our international expansion plans are progressing as expected and we have made two strategic acquisitions. We remain in a strong position to continue to grow the business and deliver returns to our shareholders.”
Ian Page, Chief Executive Officer
Highlights
- Trading in our first half was strong with Group revenue growth, including Genera, of 14.9% at Constant Exchange Rate (CER) (9.7% at Actual Exchange Rate (AER)) and underlying operating profit growth of 24.2% at CER (13.9% at AER).
- Excluding Genera, revenue growth was 11.1% at CER (6.4% at AER).
- Revenue growth in EU Pharmaceuticals, including Genera, was encouraging at 8.1% (CER), however it continues to be adversely impacted by exchange rate headwinds (0.9% growth at AER).
- North America’s excellent momentum continues with revenue growth of 51.9% at CER (59.1% at AER).
- Zycortal®, a novel canine endocrine product for the treatment of Addison’s disease, has received regulatory approvals. Two Food producing Animal Products (FAP) antibiotics, Phenocillin and Solamocta®, have also been approved in the EU.
- The integration of Genera, acquired in October 2015, is on track.
- The underlying diluted EPS increased by 17.6% at CER (7.2% at AER) to 21.99 pence per share.
- Following the Genera acquisition and the investment in the US expansion, our reported net debt is £17.8 million as at 31 December 2015 (2014: net cash £3.0 million).
- Interim dividend increased to 5.55 pence, an increase of 8.4% compared to the prior year.
To read full press release, please click here.
